Ernexa Therapeutics推进ERNA-101,剑指铂耐药卵巢癌IND申报

美股速递
Yesterday

Ernexa Therapeutics宣布,将积极推进其候选药物ERNA-101,目标直指铂耐药性卵巢癌的临床试验申请(IND)提交。这一战略举措,彰显了公司在肿瘤治疗领域的坚定决心与前瞻布局。目前,该公司正全力加速相关研发进程,力求早日为患者带来新的治疗希望。此举,也被业界视为其深耕精准医疗的重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10